HC Wainwright Raises Earnings Estimates for CalciMedica

CalciMedica Inc. (NASDAQ:CALC) – Research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for CalciMedica in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($1.93) per share for the year, up from their prior forecast of ($5.25). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($5.25) per share. HC Wainwright also issued estimates for CalciMedica’s Q4 2026 earnings at ($0.41) EPS, FY2027 earnings at ($1.61) EPS and FY2028 earnings at ($1.93) EPS.

A number of other research analysts have also weighed in on CALC. Wall Street Zen lowered CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. Guggenheim began coverage on shares of CalciMedica in a report on Thursday, August 20th. They set a “buy” rating for the company. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. Finally, Weiss Ratings upgraded shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CalciMedica currently has an average rating of “Hold” and a consensus target price of $50.00.

CalciMedica Stock Down 9.5%

Shares of CALC opened at $1.24 on Thursday. The stock has a 50 day moving average price of $1.57 and a 200 day moving average price of $3.25. CalciMedica has a one year low of $1.00 and a one year high of $36.00. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. The stock has a market capitalization of $8.47 million, a price-to-earnings ratio of -0.28 and a beta of 0.84.

CalciMedica (NASDAQ:CALC) last released its earnings results on Tuesday, November 10th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $1.03.

Institutional Investors Weigh In On CalciMedica

A hedge fund recently raised its position in CalciMedica stock. Renaissance Technologies LLC grew its holdings in CalciMedica Inc. (NASDAQ:CALC) by 45.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 128,075 shares of the company’s stock after acquiring an additional 39,775 shares during the period. Renaissance Technologies LLC owned about 0.81% of CalciMedica worth $69,000 as of its most recent filing with the Securities & Exchange Commission.

About CalciMedica

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses. CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.